Although these conflicting results question the promising role of PPARα in AD therapy, previous results indicate that expression levels of PPARα and β/δ are significantly reduced, whereas PPARγ expression is selectively increased in AD brains [226], indicating that PPARs function is impaired in AD and therefore may contribute to the progression of the disease. This evidence concerns the gene PPARA and Alzheimer disease.